COMMUNIQUÉS West-GlobeNewswire

-
475,000 members and counting: HOOPP adds 33 new employers in 2024
24/01/2025 -
Gelteq Appoints Matthew Jones as Head of Sports Performance
24/01/2025 -
Sword Health Acquires Surgery Hero to Accelerate Global Growth and Expand its Presence in the UK
24/01/2025 -
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
24/01/2025 -
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
24/01/2025 -
Director/PDMR Shareholding
24/01/2025 -
Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive License and Distribution Agreement and Minority Investment with Sanara MedTech Inc.
24/01/2025 -
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
24/01/2025 -
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
24/01/2025 -
Dermatology Group of Arkansas Welcomes a New Registered Nurse
24/01/2025 -
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
24/01/2025 -
NADP Foundation Announces 2025 Grants to Advance Access to Oral Healthcare
23/01/2025 -
Impact BioMedical Inc. to Present at The Microcap Conference
23/01/2025 -
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
23/01/2025 -
Vincerx Pharma, Inc. Announces Reverse Stock Split
23/01/2025 -
Intuitive Announces Fourth Quarter Earnings
23/01/2025 -
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
23/01/2025 -
Grant of Restricted Stock Units and Warrants to Employees in Genmab
23/01/2025 -
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
23/01/2025
Pages